Drug Trial Radar · NCT01341652
Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Jan 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
99
Actual
Start
May 23, 2011
Primary completion
Jun 30, 2020
Study completion Jun 30, 2020
Sponsor
- Lead sponsor
- University of Wisconsin, MadisonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 26, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators are trying to find new methods to treat prostate cancer. The approach the investigators are taking is to try to enhance patients' own immune response against the cancer. In this study the investigators will be testing the effectiveness of a vaccine that may be able to help the body fight prostate cancer.
Conditions
- Prostate Cancer
Interventions
pTVG-HPBiological
pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
rhGM-CSFBiological
rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
Primary outcomes
What the sponsor says the trial is designed to measure.
- 2-year Metastasis-Free Survival RateTime frame: 2 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.